Loss of CYLD activity has been correlated with more aggressive behavior in cutaneous squamous cell carcinoma [33], melanoma [13, 34], pancreatic carcinoma [35], and hepatocellular carcinoma [15]. This evidence concerns the gene CYLD and exocrine pancreatic carcinoma.